NEW YORK, Dec. 2 Reportlinker.com announces that a new market research report is available in its catalogue:
Multiple Myeloma Therapeutics - US Market Trends & Analysis
Advertisement
http://www.reportlinker.com/p0164271/Multiple-Myeloma-Therapeutics---US-Market-Trends--Analysis.html
Given the severity, and relentless relapses of the disease, the push to develop efficient therapies and treatments to battle the disease and improve patient survival rates and quality of life, has been especially strong. Unfazed research and development activities, have over the years, resulted in commendable advances in treatment therapies and procedures. Although patients today have a broader choice of treatments than before, the objective of all the treatment therapies is to slower the growth of malignant myeloma cells rather than elimination, and offer palliative care such as, reduction in disease symptoms, such as, fatigue, anemia, bone pain, and recurrent infections, among others.
Advertisement
These and other market data and trends are presented in "Multiple Myeloma Therapeutics: US Market Trends & Analysis" by BizAcumen, Inc. Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses.
MULTIPLE MYELOMA THERAPEUTICS BMR-1071
CONTENTS
1. METHODOLOGY 1
Study Reliability and Reporting Limitations 1
Disclaimers 2
Quantitative Techniques & Reporting Level 3
2. MARKET OVERVIEW 3
Hematological Cancer Therapies: A Prelude 3
Treatment Regimes: The Golden Rule 4
Multiple Myeloma: A Second Most Common Hematological Cancer 5
Treatment Therapies: Move Up the Learning Curve 6
Risk-Adapted Therapy: The New Norm of Future Treatment 7
New Generation Drugs in the Arsenal Against Multiple Myeloma 7
Velcade® (Bortezomib) 7
Thalomid® (Thalidomide) 7
Revlimid® (Lenalidomide) 8
Alkeran (Melphalan) 8
Doxil (Liposomal Doxorubicin) 9
Trisenox® (Arsenic trioxide) 9
Noteworthy Issues Related to Major Drugs: An Evaluation of
Pros and Cons 9
Revlimid Overtakes Thalomid: Why? 9
How Effective Will Thalomid Be in the 3rd Line Setting?
Skepticism Overflows 10
Revlimid Impedes Stem Cell Harvesting!!: What's the Truth? 10
1st & 2nd Generation Geldanamycin Analog to Do Wonders for
Myeloma Treatment 10
Other Trends & Issues 11
Approval of New Generation Drugs Push the Market Into the
Bulge Bracket 11
Growth Fundamentals Get Stronger 11
Multidrug Resistance: A Challenge to Reckon With 12
Gene Therapy Exudes Hope 12
Challenges Encountered in Clinical Trials 12
FDA's Antidotes 13
Europe Lagging Behind in Drug Approvals 14
Market Share Statistics 15
Oncology and Hematology Market 16
Drugs Approved & In Pipeline: A Review 16
Multiple Myeloma Drugs Approved by the FDA As of the Year 2008 16
Multiple Myeloma Drugs in Pipeline in the US As of the Year
2008 17
Phase III Drugs in Pipeline 17
Phase II Drugs in Pipeline 18
Phase I Drugs in Pipeline 25
Key Non-Profit Organizations in the US 29
Multiple Myeloma Research Foundation (MMRF) 29
National Coalition for Cancer Survivorship (NCCS) 29
National Marrow Donor Program (NMDP) 29
Oregon Health and Science University Cancer Institute 29
3. PRODUCT FACTS 30
Drugs 30
Lines of Treatment 30
4. CORPORATE DEVELOPMENTS 31
NICE Grants Approval for Use of Revlimid® 31
SWOG Announces Closure of Phase III Trial (S0232) for Paitents
with Multiple Myeloma 31
CytRx to Acquire Innovive 32
Launch of Epoetin alfa Hexal 32
PDL and Bristol-Myers Signs Agreement 32
MNKD and LLS Conclude Joint Research Agreement 33
MorphoSys and DSM Enter into Agreement 33
StemCyte Enters into Joint Venture with Cadila and Apollo
Hospitals in India 33
ImmunoCellular Acquires Molecular Antibody Technology 34
US House of Representatives Sanction the Hematological Cancer
Research Investment and Education Act 34
Bayer and Cell Therapeutics Enter into Mutual Agreement 34
Bristol-Myers to Take Over Kosan Biosciences 35
Bristol and PDL BioPharma Enter into Agreement 35
Gamida Cell Enters Into a Agreement with Amgen 35
Circadian Acquires Complete Stake in Vegenics 35
Takeda Acquires Millennium Pharmaceuticals 36
Fujimoto Pharmaceutical Receives Approval to Market Thalidomide 36
Celgene Obtains Health Canada Approval for Revlimid Oral
Cancer Drug 36
FDA Grants Orphan-Drug Designation to Melphalan 37
Merck Commences Phase b and Phase III Clinical Trial of
Zolinza 37
Clavis Initiates Phase II Trial of Elacytarabine 38
Gilead Sciences Commences GS 9219 Phase I Clinical Trial 38
AstraZeneca Carries Out AZD 0530 Phase II trial 38
European Commission Grants Approval of Thalidomide for
Multiple Myeloma 38
EMEA Issues Positive Opinion for Thalidomide Use in Multiple
Myeloma 38
Global Regulatory Developments for the Use of Revlimid® in
Multiple Myeloma 39
Takeda Gains FDA Approval to Promote Velcade 39
Health Canada Approves VELCADE 40
Genzyme Receives FDA Certification for Mozobil 40
Celgene's Thalidomide Pharmion Receives Marketing Authorization 41
GlaxoSmithKline Forms Alliance with OncoMed for Developing
Cancer Therapeutics 41
Cyclacel Signs Agreement to Acquire ALIGN Pharmaceuticals 41
Biogen and Genentech to Jointly Develop and Commercialize New
Blood Cancer Drug 42
Aegera Therapeutics Acquires LymphoSign Inc 42
Velcade Gains Subsidy 43
Inex Pharmaceuticals Spins Off Biotechnology Business into
Tekmira Pharmaceuticals 43
MilleGen Enters into Collaboration with LFB 43
Access Pharmaceuticals to Acquire Somanta 43
TopoTarget to Acquire Apoxis SA 43
Genentech Inks Exclusive Global Licensing Agreement with
Seattle Genetics 44
Celgene Agrees to Acquisition of Pharmion 44
PerkinElmer Plans Acquisition of ViaCell 44
Favrille Announces Acquisition of Monoclonal Antibody Range
from Diversa 45
Johnson & Johnson Secures Contract worth US$112 Million 45
Bioniche Pharma to Acquire Branded Pharmaceutical from Nabi
Biopharmaceuticals 45
Ziopharm Commences Phase II Clinical Trial of ZIO-101 46
FDA Approves Pluristem's Pre-IND Application of PLX-I 46
Merck Pharmaceuticals Commences Phase I Study for R763 Kinase
Inhibitor 46
Swissmedic Approves Celgene's REVLIMID Oral Cancer Drug 46
Celgene's REVLIMID Receives EU's Marketing Authorization 47
FDA Approves Application of Piramal's IND-P276 Multiple
Myeloma Drug 47
Millennium Pharmaceuticals and Johnson & Johnson Initiate
Velcade® Phase II Trial 47
FDA to Consider the New Drug Application Filed for Use of
Doxil® Combined with Velcade® in Patients with Multiple
Myeloma 48
Ortho Biotech Files Application with FDA for Approval of
Combination Drug DOXIL® and VELCADE® 48
Caraco's Allopurinol Receives FDA Approval 48
5. MAJOR PLAYERS 49
Amgen Inc (USA) 49
Bristol-Myers Squibb Company (USA) 49
Kosan Biosciences, Inc. (USA) 49
Celgene Corporation (USA) 49
F. Hoffmann-La Roche Ltd Switzerland) 49
Genentech, Inc. (USA) 49
Genta Incorporated (USA) 50
Millennium Pharmaceuticals (USA) 50
Ortho Biotech Products, LP (USA) 50
Seattle Genetics (USA) 50
Ziopharm Oncology, Inc. (USA) 50
6. MARKET ANALYTICS 51
EXHIBITS
Table 1: Percentage Breakdown of Hematological Cancer Cases by
Type in the US - 2008E
Table 2: Percentage Breakdown of Drugs Used in First Line
Treatment in European Multiple Myeloma Market - 2006
Table 3: Percentage Breakdown of Drugs Used in Second Line
Treatment in European Multiple Myeloma Market - 2006
Table 4: Percentage Breakdown of Drugs Used in Third Line
Treatment in European Multiple Myeloma Market - 2006
Table 5: Market Shares of Leading Companies in the US Market
for Multiple Myeloma Therapeutics - 2006
Table 6: Market Shares of Leading Companies in the US Market
for Multiple Myeloma Therapeutics - 2013P
Table 7: Market Shares of Leading Companies in the US Market
for Oncology and Hematology - 2008E
Table 8: Multiple Myeloma Therapeutics Market by Drug in the
US: 2007-2015 (Sales in US$ Million)
Table 9: Percentage Breakdown of Multiple Myeloma Therapeutics
Market by Drug in the US for the Years 2009 & 2012
Table 10: Multiple Myeloma Therapeutics Market by Line of
Treatment in the US: 2007-2015 (Sales in US$ Million)
Table 11: Percentage Breakdown of Multiple Myeloma
Therapeutics Market by Line of Treatment in the US for the
Years 2009 & 2012
COMPANIES PROFILED
To order this report:
Therapy Industry: Multiple Myeloma Therapeutics - US Market Trends & Analysis
More Market Research Report
Nicolas BombourgReportlinkerEmail: [email protected]: (805)652-2626Intl: +1 805-652-2626
SOURCE Reportlinker
